Trial Profile
A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION-827359, an Antisense Oligonucleotide Inhibitor of ENaC, Administered to Healthy Volunteers and Patients With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jun 2021
Price :
$35
*
At a glance
- Drugs Cofirasersen (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals
- 19 May 2021 Results presented at the 117th International Conference of the American Thoracic Society
- 02 Feb 2021 Status changed from active, no longer recruiting to completed.
- 13 Oct 2020 According to an Ionis Pharmaceuticals media release, data from the Phase 1 study will be presented via e-poster at the 2020 North American Cystic Fibrosis Conference, which will hold virtual sessions and discussions 21st to 23rd Oct 2020.